Impact BioMedical, Inc. (IBO)
0.54
+0.06
(+12.50%)
USD |
NYAM |
Sep 04, 16:00
0.5174
-0.02
(-4.19%)
After-Hours: 20:00
Impact BioMedical Research and Development Expense (Quarterly) : 0.076M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.076M |
| March 31, 2026 | 0.046M |
| December 31, 2025 | 0.11M |
| September 30, 2025 | 0.052M |
| June 30, 2025 | 0.075M |
| March 31, 2025 | 0.103M |
| December 31, 2024 | |
| September 30, 2024 | 0.082M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.183M |
| December 31, 2023 | 0.463M |
| September 30, 2023 | 0.239M |
| June 30, 2023 | 0.266M |
| March 31, 2023 | 0.179M |
| Date | Value |
|---|---|
| December 31, 2022 | 0.522M |
| September 30, 2022 | 0.33M |
| June 30, 2022 | 0.206M |
| March 31, 2022 | 0.168M |
| December 31, 2021 | 0.435M |
| September 30, 2021 | 0.1897M |
| June 30, 2021 | 0.2114M |
| March 31, 2021 | 0.2439M |
| December 31, 2020 | 0.1721M |
| September 30, 2020 | 0.1225M |
| June 30, 2020 | 0.1471M |
| March 31, 2020 | 0.072M |
| September 30, 2019 | 0.0795M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | 0.00 |
| Enveric Biosciences, Inc. | 1.355M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |